FDA Approval of Development Programme

News Release

3 February 2014

Consort Medical plc

FDA Approval of Development Programme

Consort Medical plc ("Consort Medical") (LSE: CSRT), is delighted to announce that its development programme INJ300 has been granted FDA approval.

Bespak's INJ300 development programme is an autoinjector for Sumatriptan by Dr. Reddy's Laboratories. This is the first Bespak autoinjector programme to receive regulatory approval, following the acquisition of The Medical House.

Preparations are underway for product launch which is expected in Q1 2014, ahead of our previous expectations.

Jonathan Glenn, Consort Medical's Chief Executive commented: "This regulatory approval of our first autoinjector represents a major milestone for Consort Medical's Injectables technology, and is a significant step in the execution of our diversification strategy."

Consort Medical's Interim Management Statement will be released on 19 March 2014.

-Ends-

Enquiries:

Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.